Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

The Associated Press November 5, 2010, 4:44PM ET

AstraZeneca, Bristol-Myers diabetes drug approved

Drug makers Bristol-Myers Squibb Co. and AstraZeneca PLC said Friday that they received U.S. marketing approval for a once-a-day diabetes drug that combines the starter diabetes drug metformin with the companies' newer drug Onglyza.

The companies said the Food and Drug Administration approved Kombiglyze XR as a treatment for type 2 diabetes in adults. Kombiglyze is an extended release pill intended to be taken once a day to help control blood sugar levels. Bristol-Myers and AstraZeneca are partners on Onglyza, which was approved in August 2009. Metformin is an inexpensive drug often used as a first option for diabetes patients.

Kombiglyze is intended for use along with diet and exercise and has not been studied as a treatment for type 1 diabetes or in combination with insulin, the companies said.

Shares of Bristol-Myers, based in Princeton, N.J., dipped 14 cents to close at $26.69. Shares of London-based AstraZeneca rose 5 cents to close at $50.10.

BW Mall - Sponsored Links

Buy a link now!